SAB Biotherapeutics (SABS) Net Cash Flow (2020 - 2026)

SAB Biotherapeutics has reported Net Cash Flow for 7 years, with the latest figure at $10.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 403.09% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $15.1 million (up 283.87% YoY), and the FY2025 full-year result was $1.8 million, up 103.83% from the prior year.
• Net Cash Flow for Q1 2026 stood at $10.0 million, up from -$18.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $54.1 million in Q4 2023, with the low at -$42.5 million in Q1 2024.
• Historically, Net Cash Flow has averaged -$1.1 million across 5 years, with a median of -$3.3 million in 2025.
• Annual changes were most pronounced in 2023 — Net Cash Flow soared 706.03% — and 2025, when it plunged 119310.81%.
• SAB Biotherapeutics' Net Cash Flow stood at $6.7 million in 2022, then soared by 706.03% to $54.1 million in 2023, then slumped by 99.97% to $15539.0 in 2024, then sank by 119310.81% to -$18.5 million in 2025, then soared by 154.0% to $10.0 million in 2026.
• The last three Net Cash Flow figures came in at $10.0 million (Q1 2026), -$18.5 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.